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The majority of patients afflicted with Duchenne muscular dystrophy develop cardiomyopathic
complications, warranting large-scale proteomic studies of global cardiac changes for the iden-
tification of new protein markers of dystrophinopathy. The aged heart from the X-linked
dystrophic mdx mouse has been shown to exhibit distinct pathological aspects of cardiomy-
opathy. In order to establish age-related alterations in the proteome of dystrophin-deficient
hearts, cardiomyopathic tissue from young versus aged mdx mice was examined by label-free
LC-MS/MS. Significant age-dependent alterations were established for 67 proteins, of which 28
proteins were shown to exhibit a lower abundance and 39 proteins were found to be increased
in their expression levels. Drastic changes were demonstrated for 17 proteins, including in-
creases in Ig chains and transferrin, and drastic decreases in laminin, nidogen and annexin.
An immunblotting survey of young and old wild-type versus mdx hearts confirmed these pro-
teomic findings and illustrated the effects of natural aging versus dystrophin deficiency. These
proteome-wide alterations suggest a disintegration of the basal lamina structure and cytoskele-
tal network in dystrophin-deficient cardiac fibres, increased levels of antibodies in a potential
autoimmune reaction of the degenerating heart, compensatory binding of excess iron and a
general perturbation of metabolic pathways in dystrophy-associated cardiomyopathy.
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1 Introduction
Duchenne muscular dystrophy is the most frequent neuro-
muscular disorder in humans and is characterised by the
primary deficiency in the membrane cytoskeletal protein dys-
trophin [1]. Absence of the Dp427 isoform of dystrophin
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Abbreviation: mdx, muscular dystrophy x-linked
triggers a significant reduction in a number of sarcolem-
mal glycoproteins and causes a variety of downstream ab-
normalities in cell signalling, excitation-contraction coupling
and ion homeostasis, as well as enhanced proteolytic destruc-
tion of muscle-associated proteins [2]. Disintegration of sar-
colemmal integrity renders dystrophin-deficient fibres more
susceptible to necrosis and eventually causes severe muscle
wasting [3]. Importantly, cardiac dysfunction is a common
clinical manifestation in neuromuscular disorders [4], par-
ticularly in hereditary muscular dystrophies [5]. During the
second decade of life, the majority of patients afflicted with
X-linkedmuscular dystrophy show serious cardiac abnormal-
ities [6], including cardiomyopathy, regional wall abnormali-
ties and cardiac dysrhythmia [7].
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Since the age of onset of cardiomyopathy in dystrophic
children varies considerably and because skeletal muscle
weakness and heart disease do not correlate, cellular fac-
tors other than dystrophin deficiency are believed to con-
tribute to cardiomyopathy [8]. Overt cardiomyopathy dras-
tically increases with age. More than 80% of teenage boys
with muscular dystrophy show abnormal systolic function,
resulting in fatal cardiac complications in a large number
of cases [9]. Pathological hallmarks of cellular changes in
muscular dystrophy-associated cardiomyopathy include in-
terstitial inflammation, fatty tissue replacement, fibrosis and
surface membrane degradation of cardiac tissue [10]. Since
dystrophin-deficient cardiac fibres have only a limited regen-
erative capacity, the gradual replacement of cardiac fibres by
non-contractile tissue results in progressive functional de-
cline of the dystrophic heart [6].
Previous proteomic investigations of dystrophin-deficient
muscle tissues have focused on mildly affected extraocular
muscle, moderately necrotic limb muscles and severely dys-
trophic diaphragm muscle from the mdx mouse [2, 11, 12],
an established animal model of Duchenne muscular dystro-
phy [13]. With respect to cardiac muscle, proteomic profiling
of the immunoprecipitated dystrophin complex has estab-
lished potential new binding partners of cardiac Dp427 [14]
and metabolomic and proteomic studies have established the
diverse effects of dystrophin deficiency on 9-month-old dys-
trophic heart tissue [15, 16]. Importantly, the natural aging
process itself is a major risk factor for cardiovascular dis-
ease. Intrinsic cardiac aging is associated with ventricular hy-
pertrophy, increased fibrosis, atrial fibrillation and decreased
maximal contractile capacity [17].
This makes the determination of protein changes in
the senescent mouse model of severe muscular dystrophy-
associated cardiomyopathy a crucial undertaking for the char-
acterisation of this naturally occurring genetic animal model.
Proteomic studies of the aging rodent heart have established
changes in the concentration of metabolic enzymes, as well
as components of cell signalling, the immune response, ox-
idative stress and structural support [18–20]. In analogy to
these investigations of normal heart tissues during aging,
this proteomic study has determined changes from 7-wk-old
to 20-month-old mdx hearts that lack dystrophin. Aged dys-
trophic hearts clearly exhibited a generally perturbed protein
expression pattern with drastic changes in cardiac proteins
involved in basal lamina stabilisation, cytoskeletal organisa-
tion, iron binding, antibody response, fibre contraction and
energy metabolism.
2 Materials and methods
2.1 Materials
Analytical grade chemicals and materials used for the MS-
based proteomic profiling of dystrophic hearts were obtained
fromAmershamBiosciences/GEHealthcare (Little Chalfont,
Buckinghamshire, UK) and BioRad Laboratories (Hemel-
Hempstead, Hertfordshire, UK). Sequencing grade modi-
fied trypsin and Lys-C were from Promega (Madison, WI,
USA). Chemiluminescence substrate and protease inhibitors
were purchased from Roche Diagnostics (Mannheim, Ger-
many). Whatman NC transfer membranes were from Invit-
rogen (Carlsbad, CA, USA). Primary antibodies were pur-
chased from Abcam, Cambridge, UK (ab41803 to annexin;
ab34830 to malate dehydrogenase; ab110330 to pyruvate de-
hydrogenase; ab71440 to aconitase; ab43176 to ATP synthase;
ab9033 to transferrin; ab14734 to VDAC-1; ab14511 to nido-
gen) and Sigma Chemical Company, Dorset, UK (L9393 to
laminin). Secondary peroxidase-conjugated secondary anti-
bodies were obtained from Chemicon International (Temec-
ula, CA, USA). All other chemicals were purchased from
Sigma Chemical Company (Dorest, UK).
2.2 X-linked dystrophic mdx mouse model
Duchenne muscular dystrophy is caused by primary abnor-
malities in the dystrophin gene of the humanX-chromosome.
In analogy, the established mdx animal model is missing the
full-length dystrophin isoformDp427 due to a pointmutation
in exon 23 [13]. In order to study global age-related changes
in the dystrophic heart proteome, cardiac muscle tissue from
7-wk-oldmdxmice, 20-month-oldmdxmice, 7-wk-old control
C57 mice and 20-month-old control C57 mice were obtained
from the animal facility of the University of Bonn [21]. Mice
were kept under standard conditions and all procedures were
carried out in accordance with Irish and German guidelines
on the use of animals for scientific experiments. Animals
were sacrificed by cervical dislocation and their hearts imme-
diately quick-frozen in liquid nitrogen.
2.3 Preparation of tissue extracts from normal and
dystrophic heart muscle
The preparation of mdx cardiac tissue was carried out by
a previously optimised method [16]. Hearts from 7-wk-old
mdx mice (n = 4) and 20-month-old mdx mice (n = 4), as
well as age-matched normal mice, were washed with PBS to
remove excess blood and then cardiac tissue (100 mg) was
finely chopped and homogenised in 0.5 M HEPES, pH 7.4,
200mMEGTA, 10%w/v sucrose, 3mMmagnesiumchloride,
and 0.1% w/v sodium azide, using a hand held Kontes Pellet-
Pestle Motor homogeniser. To prevent proteolytic degrada-
tion of sensitive cardiac muscle proteins, the buffer was
supplemented with a protease inhibitor cocktail [22]. Car-
diac tissue samples were ground into a fine powder in liq-
uid nitrogen using a pestle and mortar. The tissue powder
was re-suspended in lysis buffer (9.5 M urea, 2% CHAPS,
0.8% ampholytes pH 3–10, 1% DTT and a protease inhibitor
cocktail) at a ratio of 1:10 w/v. Crude extracts were gently
shaken at 4C for 2 h using a Thermomixer from Eppendorf
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(Hamburg, Germany). Following centrifugation at 4C for
20 min at 14 000 × g, the supernatant fractions from normal
and dystrophic preparations were removed and used for the
comparative gel electrophoretic separation of the urea-soluble
protein repertoire from heart muscle.
2.4 Sample preparation for label-free LC-MS/MS
analysis
Crude cardiac samples were pre-treated with the Ready Prep
2D clean up kit from BioRad Laboratories. The resulting
protein pellets were re-suspended in label-free solubilisation
buffer, consisting of 6 M urea, 2 M thiourea and 10 mM Tris,
pH 8.0 in LC-MS grade water [23, 24]. Protein suspensions
were vortexed, sonicated and centrifuged to ensure pellets
were fully re-suspended and then their protein concentration
wasdetermined [22]. For label-freeMSanalysis, volumeswere
kept to a minimum and initially equalised using label-free
solubilisation buffer. Samples were reduced for 30 min with
10 mMDTT and alkylated for 20 min in the dark with 25 mM
iodoacetamide in 50mM ammonium bicarbonate. The initial
proteolytic digestion was carried out with sequencing grade
Lys-C at a ratio of 1:100 (protease/protein) for 4 h at 37C. The
samples were subsequently diluted with four times the initial
sample volume in 50 mM ammonium bicarbonate. A second
digestion step was performed with sequencing grade trypsin
at a ratio of 1:25 (protease/protein) overnight at 37C. Prior to
MS analysis, the digested protein preparations were diluted
3:1 v/v with 2% TFA in 20% ACN, vortexed and sonicated to
ensure an even suspension.
2.5 Label-free LC-MS/MS analysis
An Ultimate 3000 nanoLC system (Dionex) coupled to a an
LTQ Orbitrap XL mass spectrometrer from Thermo Fisher
Scientific (Dublin, Ireland) was employed for nano LC–
MS/MS analysis in the Proteomics Facility of the NICB,
Dublin City University, as previously described by Meleady
et al. [23, 24]. Digested peptide mixtures (5 L volume) were
loaded onto a C18 trap column (C18 PepMap, 300 m id ×
5mm, 5 mparticle size, 100 A˚ pore size; Dionex). Desalting
was carried out at a flow rate of 25 L/min in 0.1% TFA for
10min. The trap columnwas switched on-line with an analyt-
ical PepMap C18 column (75m id × 250mm, 3mparticle
and 100 A˚ pore size; Dionex). Peptides generated from car-
diac proteins were eluted with the following binary gradients:
solvent A (2% ACN and 0.1% formic acid in LC-MS grade
water) and 0–25% solvent B (80% ACN and 0.08% formic
acid in LC-MS grade water) for 240 min and 25–50% sol-
vent B for a further 60 min. The column flow rate was set to
350 nL/min [24]. Data were acquired with Xcalibur software,
version 2.0.7 (Thermo Fisher Scientific). The MS apparatus
was operated in data-dependent mode and externally cali-
brated. Survey MS scans were acquired in the Orbitrap in
the 400–1800 m/z range with the resolution set to a value of
30 000 at m/z 400 and lock mass set to 445.120025 u. CID
fragmentation was carried out in the linear ion trap with up to
seven of the most intense ions (1+, 2+ and 3+) per scan [23].
Within 40 s, a dynamic exclusion window was applied. A
normalised collision energy of 35%, an isolation window of
3m/z and onemicroscanwere used to collect suitable tandem
mass spectra [23, 24].
2.6 Quantitative profiling by label-free LC-MS/MS
analysis
Progenesis label-free LC-MS software version 3.1 from Non-
LinearDynamics (Newcastle uponTyne,UK)was used to pro-
cess the raw data generated from LC-MS/MS analysis. Data
alignment was based on the LC retention time of each sam-
ple, allowing for any drift in retention time given and adjusted
retention time for all runs in the analysis [23]. A reference run
was established with the sample run that yielded most fea-
tures (i.e. peptide ions). The retention times of all of the other
runs were aligned to this reference run and peak intensities
were then normalised. Prior to exporting the MS/MS output
files to MASCOT (www.matrixscience.com) for protein iden-
tification, a number of criteriawere employed tofilter the data.
These data included (i) peptide features with ANOVA < 0.05
between experimental groups, (ii) mass peaks (features) with
charge states from +1, +2, +3, and (iii) greater than one iso-
tope per peptide [23]. A MASCOT generic file was generated
from all exported MS/MS spectra from Progenesis software.
The MASCOT generic file was used for peptide identifica-
tion with MASCOT (version 2.2) and searched against the
UniProtKB-SwissProt database (downloaded in April 2012)
with 16 521 proteins (taxonomy: Mus musculus). The follow-
ing search parameters were used for protein identification:
(i) MS/MS mass tolerance set at 0.5 Da, (ii) peptide mass tol-
erance set to 10 ppm, (iii) carbamidomethylation set as a fixed
modification, (iv) up to two missed cleavages were allowed
and (v) methionine oxidation set as a variable modification.
For further consideration and re-importation back into Proge-
nesis LC–MS software for further analysis, only peptides with
ion scores of 40 and above were chosen [24]. Importantly, the
following criteria were applied to assign a heart-associated
protein as properly identified: (i) an ANOVA score between
experimental groups of ≤0.05, (ii) proteins with ≥2 peptides
matched and (iii) a MASCOT score >40 [23, 24].
2.7 Verification of key proteomic hits by
immunoblotting
In order to confirm altered concentration levels of dis-
tinct muscle proteins revealed from label-free LC-MS/MS
analysis, immunoblotting was employed. 1DE and im-
munoblotting were carried out by a previously described
method [25]. Electrophoretic separation of cardiac proteins
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from 7-wk-old normal versus mdx mice and 20-month-old
normal versus mdx mice was performed with standard 10%
PAGE gels, followed by wet transfer at 100 V for 70 min to
Whatman Protan NC sheets in a Transblot Cell from BioRad
Laboratories. Membranes were blocked for 1 h with a milk
protein solution (consisting of 5% w/v fat-free milk pow-
der in 10% PBS) to prevent non-specific antibody binding.
NC sheets were incubated with sufficiently diluted primary
antibodies to a variety of identified cardiac proteins for 3 h
with gentle agitation at 4C. Following several washing steps,
membranes were incubated for 1 h at 4C with secondary an-
tibodies. Peroxidase-conjugated antibodies were sufficiently
diluted in blocking solution to prevent non-specific binding.
Immuno-decorated protein bands were then visualised on
washedmembranes by the ECLmethod. Densitometric scan-
ning and evaluation of immunoblots was performed with a
HP PSC-2355 scanner and ImageJ (NIH, USA) and Graph-
Pad Prism (San Diego, CA, USA) software.
3 Results
Proteomic profiling of 7-wk-old versus 20-month-old mdx
hearts was carried out to determine the extent of age-related
protein changes in muscular dystrophy-associated cardiomy-
opathy. Following the determination of protein alterations
by a label-free LC-MS/MS approach, key proteomic findings
were verified by immunblotting of young and aged wild-type
versus age-matched mdx hearts to differentiate between the
effects of the natural aging process versus the lack of dys-
trophin in the mdx heart.
3.1 Proteomic profiling of 7-wk-old heart tissue
from normal versus mdx mice
A label-free LC-MS analysis of 7-wk-old normal cardiac sam-
ples versus age-matched mdx samples was used to estab-
lish differences between unaffected and dystrophin-deficient
heart tissue. The comparative proteomic profiling study re-
vealed moderate changes in 20 heart-associated proteins
(Table 1), agreeing with the mild cardiomyopathic pheno-
type in young dystrophic mice. An increased abundance
was shown for actin, biglycan, protein disulphide isomerase,
calreticulin, the mitochondrial enzymes succinyl-CoA:3-
ketoacid-coenzyme A transferase, 2-oxoglutarate dehydroge-
nae and isocitrate dehydrogenase, as well as the glycolytic
enzyme phosphofructokinase. In contrast, slightly decreased
levels were found for troponin TnT, aortic actin, selenium-
binding protein and glyceraldehyde-3-phosphate dehydro-
genase, as well as the mitochondrial enzymes succinyl-
CoA ligase, methylmalonate-semialdehyde dehydrogenase,
3-hydroxyacyl-CoA dehydrogenase, 2,4-dienoyl-CoA reduc-
tase, 3-ketoacyl-CoA thiolase and glutamate dehydrogenase.
3.2 Label-free LC-MS/MS analysis of the aged
dystrophin-deficient mdx heart
Since aging drastically accelerates the dystrophy-related car-
diomyopathic phenotype of the mdx model of Duchenne
muscular dystrophy, label-free LC-MS/MS analysis of 7-wk-
old versus 20-month-old mdx hearts was performed to de-
termine global changes in dystrophin-deficient cardiac tis-
sue. Significant changes were found in 67 proteins, whereby
39 proteins were shown to be increased in abundance and
a decreased expression was determined for 28 proteins
(Table 2). Besides moderate changes in 50 heart-associated
proteins, positive or negative alterations above a 2.5-fold
change were shown in 17 proteins. Proteins with a drastically
increased density were identified as various Ig chains, mito-
chondrial beta-hydroxybutyrate dehydrogenase, ferritin light
and heavy chain, catalase and transferrin. Considerable re-
ductions were shown for lamin, laminin, myosin light chain,
nidogen, vimentin and long chain fatty acid ligase. A variety
of cardiac proteins were marginally affected in a differential
manner andMS analysis identified them as proteins involved
inmuscle contraction, mitochondrial metabolism, glycolysis,
ion handling, cytoskeletal organisation and the cellular stress
response.
3.3 Immunoblot analysis of aged normal versus
aged mdx heart
Since the label-free LC-MS/MS analysis shown here has fo-
cused on age-related effects in the mdx heart, immunoblot-
ting was used to verify key proteomic findings and also to
compare the expression levels of identified proteins in nor-
mal versus dystrophic preparations. Figures 1 and 2 show
the immunoblot survey of 7-wk-old normal hearts, 7-wk-old
mdx hearts, 20-month-old normal hearts and 20-month-old
mdx hearts. Silver staining of crude tissue extracts from the
four different heart preparations did not show extensive dif-
ferences in their overall 1D banding pattern following SDS-
PAGE analysis, but slight variations in the intensity of indi-
vidual bands (Fig. 1A). A variety of antibodies were evaluated
and representative immunoblots with reliable staining pat-
terns are shown in Figs. 1 and 2. The increase in transfer-
rin was confirmed by immunoblotting, although differences
were not found to be statistically significant (Fig. 1B). The
drastic decrease in the expression levels of laminin, nidogen
and annexin during aging of the mdx heart were found to
be statistically significant (Fig. 1C, E, F). Labelling with spe-
cific antibodies to these three cardiac proteins clearly verified
the proteomic findings listed in Table 2. Importantly, while
the concentration of laminin, nidogen and annexin increased
during natural aging, the deficiency in dystrophin caused the
opposite effect (Fig. 1C, E, F). No significant alterations in
the expression of ATP synthase were found (Fig. 1D).
A previous gel-based study of the dystrophic heart has
shown reduced levels of many mitochondrial and metabolic
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Table 1. List of changed proteins in 7-wk-old mdx heart tissue versus age-matched normal controls as determined by label-free MS/MS
analysis
Accession number Protein name Peptides Score Anova Fold change
P68134 Actin, alpha, muscle 3 141.67 0.03 2.30
P28653 Biglycan 2 104.16 0.02 1.77
P09103 Protein disulphide-isomerase 3 127.77 0.01 1.51
P27773 Protein disulphide-isomerase A3 3 145.22 0.02 1.47
Q9D0K2 Succinyl-CoA:3-ketoacid-coenzyme A
transferase 1, mitochondrial
2 143.54 0.02 1.43
Q8BFZ3 Beta-actin-like protein 2 2 93.12 0.05 1.41
Q60597 2-Oxoglutarate dehydrogenase, mitochondrial 2 97.42 0.02 1.38
P14211 Calreticulin 2 90.7 3.71E-03 1.29
P54071 Isocitrate dehydrogenase [NADP],
mitochondrial
3 215.87 0.03 1.28
P47857 6-Phosphofructokinase, muscle type 2 138.74 0.03 1.25
P26443 Glutamate dehydrogenase 1, mitochondrial 2 102.33 0.02 −1.23
Q8BWT1 3-Ketoacyl-CoA thiolase, mitochondrial 3 220.83 0.02 −1.24
P16858 Glyceraldehyde-3-phosphate dehydrogenase 3 245.05 0.01 −1.25
P17563 Selenium-binding protein 1 3 144.51 0.02 −1.36
Q9CQ62 2,4-Dienoyl-CoA reductase, mitochondrial 2 147.96 8.71E-03 −1.38
O08756 3-Hydroxyacyl-CoA dehydrogenase type-2 2 154.83 0.03 −1.41
Q9EQ20 Methylmalonate-semialdehyde dehydrogenase
[acylating], mitochondrial
4 198.45 2.62E-03 −1.43
Q9Z2I9 Succinyl-CoA ligase [ADP-forming] subunit
beta, mitochondrial
3 152.4 7.12E-03 −1.49
P62737 Actin, aortic smooth muscle 2 95.23 1.12E-03 −1.62
P50752 Troponin T, cardiac muscle 2 101.51 0.01 −1.68
proteins [16]. To correlate the findings fromour aging study to
these previously established alterations in the mdx heart, an-
tibody labelling of crucial metabolic enzymes and mitochon-
drial markers was employed. Immunoblotting of pyruvate
dehydrogenase, aconitase andmalate dehydrogenase demon-
strated a significant reduction of these metabolic enzymes
during aging of cardiacmuscle from themdxmouse (Fig. 2A–
C). The mitochondrial marker protein VDAC1 also showed
reduced levels in 20-month-old mdx hearts as compared to
younger dystrophic hearts (Fig. 2D). The analysis of antibody
labelling to lamin, myosin light chain and vimentin did not
result in significant differences between young versus aged
mdx preparations (not shown).
4 Discussion
A variety of novel pharmacological, cellular and genetic ap-
proaches are currently tested to counteract the symptoms
of dystrophinopathies [26], including the treatment of car-
diomyopathic complications [6]. To better monitor the ther-
apeutic success of experimental treatments and evaluate po-
tential side effects, as well as generally improve diagnostic
procedures, there is an urgent need for superior biomark-
ers of X-linked muscular dystrophy and associated cardiomy-
opathy. Experimental models of Duchenne muscular dystro-
phy exhibit many of the symptoms of cardiovascular disease
seen in patients and are therefore frequently employed in
pre-clinical investigations [27]. Dystrophin-deficient tissues
are widely used as drug testing systems, including mdx heart
preparations [28]. The mdx mouse is missing dystrophin due
to a pointmutation in exon 23 [13] and showsmany secondary
abnormalities of the dystrophic phenotype [29]. Deficiency in
cardiac dystrophin is associated with a variety of biochemical,
physiological and cellular abnormalities, including a reduc-
tion in dystrophin-associated glycoproteins, disturbed Ca2+
signaling, a substantial decrease in luminal Ca2+-buffering
proteins, amplification of ROS-generating pathways, broad
infiltration of inflammatory cells, greater amounts of adipose
tissue, fibre necrosis and fibrosis, as well as tachycardia and
abnormal excitation–contraction–relaxation cycles in themdx
heart [30–38].
Since aging appears to accelerate the degenerative phe-
notype of the mdx heart [39–41], we have applied MS-based
proteomics to study the altered protein expression profile
of 7-wk-old versus 20-month-old dystrophic hearts. Both,
the subcellular localisation and the composition of the car-
diac dystrophin–glycoprotein complex differs from skele-
tal muscle [14, 42], which might explain how the heart
and skeletal muscle tissue are differently affected in dys-
trophinopathy. The proteomic findings presented here in-
dicate aging-associated alterations in components involved
in the contraction–relaxation cycle, bioenergetics, iron bind-
ing, nuclear integrity, extracellular matrix organisation, cy-
toskeletal maintenance and the cellular stress response. In
addition, high concentrations of antibodies were found in
cardiac mdx preparations by MS analysis. This agrees with
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Table 2. List of changed proteins in aging mdx heart tissue as determined by label-free MS/MS analysis
Accession number Protein name Peptides Score Anova Fold change
P01864 Ig gamma-2A chain, C region 4 238.19 1.43E-03 19.59
Q80XN0 D-beta-hydroxybutyrate dehydrogenase,
mitochondrial
3 201.56 7.48E-04 10.63
P01867 Ig gamma-2B chain, C region 3 130.75 1.59E-03 9.32
P01872 Ig mu chain, C region 2 129.15 5.20E-03 8.83
P01837 Ig kappa chain, C region 3 192.25 2.37E-03 4.98
P29391 Ferritin light chain 1 4 248.68 9.40E-04 4.54
P24270 Catalase 2 112.04 0.03 2.9
P09528 Ferritin heavy chain 4 281.25 1.81E-03 2.82
Q921I1 Transferrin 2 103.14 0.03 2.56
P15626 GSH transferase 6 340.24 9.70E-04 2.14
Q9DBJ1 Phosphoglycerate mutase 1 3 154.49 0.02 1.91
Q9DCM2 GSH transferase 2 128.36 5.24E-03 1.86
P54071 Isocitrate dehydrogenase [NADP],
mitochondrial
23 2050.16 5.98E-04 1.85
Q6P8J7 Creatine kinase S-type, mitochondrial 2 137.95 0.04 1.79
P17742 Peptidyl-prolyl cis-trans isomerase A 3 186.4 1.57E-03 1.76
P68134 Actin, alpha 4 273.36 3.98E-03 1.75
Q9JHI5 Isovaleryl-CoA dehydrogenase, mitochondrial 8 572.22 8.73E-04 1.68
P47738 Aldehyde dehydrogenase, mitochondrial 4 213.46 1.91E-03 1.67
P51174 Long-chain specific acyl-CoA dehydrogenase,
mitochondrial
8 513.47 2.89E-03 1.66
O70250 Phosphoglycerate mutase 2 5 269.27 0.02 1.66
P10649 GSH transferase 7 472.38 0.01 1.65
P16125 L-lactate dehydrogenase B chain 2 199.75 7.91E-04 1.58
P26041 Moesin 3 134.23 1.00E-02 1.58
P19157 GSH transferase 2 171.48 0.03 1.56
P04247 Myoglobin 8 971.05 4.14E-03 1.54
P05064 Fructose-bisphosphate aldolase A 2 89.51 0.04 1.54
P62737 Actin, aortic smooth muscle 2 207.26 5.91E-03 1.53
P62962 Profilin-1 3 190.16 1.11E-03 1.46
P60710 Actin, cytoplasmic 1 4 256.28 8.91E-03 1.45
O70468 Myosin-binding protein C, cardiac-type 3 190.42 0.01 1.45
P56565 Protein S100-A1 2 174.38 3.90E-05 1.45
Q9D0K2 Succinyl-CoA:3-ketoacid-coenzyme A
transferase 1, mitochondrial
3 333.51 7.79E-03 1.44
Q60597 2-Oxoglutarate dehydrogenase, mitochondrial 3 156.25 6.77E-03 1.41
P45376 Aldose reductase 3 177.39 0.02 1.38
Q99KI0 Aconitate hydratase, mitochondrial 17 1228.3 5.62E-05 1.36
P05201 Aspartate aminotransferase, cytoplasmic 7 504.11 2.22E-03 1.35
P06745 Glucose-6-phosphate isomerase 4 346.71 4.29E-05 1.35
P17751 Triosephosphate isomerase 2 116.97 0.02 1.29
Q8QZT1 Acetyl-CoA acetyltransferase, mitochondrial 3 164.07 6.03E-03 1.27
P52503 NADH dehydrogenase [ubiquinone]
iron-sulphur protein 6, mitochondrial
2 137.35 0.01 −1.23
P62631 Elongation factor 1-alpha 2 4 296.15 0.04 −1.26
Q9D3D9 ATP synthase subunit delta, mitochondrial 2 185.13 0.03 −1.37
Q9CQA3 Succinate dehydrogenase [ubiquinone]
iron-sulphur subunit, mitochondrial
3 201.11 0.05 −1.4
P56480 ATP synthase subunit beta, mitochondrial 10 854.08 0.04 −1.42
P10126 Elongation factor 1-alpha 1 4 232.69 0.03 −1.47
P63038 60 kDa HSP, mitochondrial 4 280.95 0.02 −1.55
P57776 Elongation factor 1-delta 2 111.73 0.03 −1.6
P68372 Tubulin beta-4B chain 2 102.84 0.05 −1.72
Q9D855 Cytochrome b-c1 complex, subunit 7 5 280 1.07E-03 −1.76
P12787 Cytochrome c oxidase, subunit 5A,
mitochondrial
5 319.85 0.01 −1.81
Q9CXZ1 NADH dehydrogenase [ubiquinone]
iron-sulphur protein 4, mitochondrial
4 229.86 0.03 −1.86
Q9DB15 39S ribosomal protein L12, mitochondrial 2 113.08 0.02 −1.88
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Table 2. Continued
Accession number Protein name Peptides Score Anova Fold change
P51667 Myosin regulatory light chain 2,
ventricular/cardiac muscle isoform
4 267.78 0.03 −1.96
P14824 Annexin A6 2 112.82 0.04 −1.96
P97450 ATP synthase-coupling factor 6, mitochondrial 5 403.38 0.03 −2.05
P61979 Heterogeneous nuclear ribonucleoprotein K 2 96.7 5.93E-03 −2.05
Q9Z2I9 Succinyl-CoA ligase [ADP-forming] subunit
beta, mitochondrial
3 172.2 0.03 −2.07
P70670 Nascent polypeptide-associated complex
subunit alpha, muscle-specific form
3 171.72 0.03 −2.08
Q99020 Heterogeneous nuclear ribonucleoprotein A/B 2 102.84 2.43E-03 −2.11
P48678 Prelamin-A/C 3 177.88 0.04 −2.67
P41216 Long-chain fatty acid–CoA ligase 1 2 120.37 2.85E-03 −2.77
P20152 Vimentin 3 146.1 0.05 −3.04
P10493 Nidogen-1 2 100.17 6.04E-03 −3.36
Q3THE2 Myosin regulatory light chain 12B 2 105.15 6.44E-03 −4.03
P02468 Laminin subunit gamma-1 5 277.53 8.68E-04 −4.22
P02469 Laminin subunit beta-1 3 171.32 5.45E-04 −4.71
P14733 Lamin-B1 2 100.13 0.01 −12.91
the general idea of autoimmune mechanisms being involved
in the molecular pathogenesis of cardiomyopathy [43]. Pos-
sibly the deficiency in cardiac dystrophin leads to structural
damage and tissue injury which in turn provokes autoimmu-
nity or triggers infiltration of antibodies. Proteomic profiling
of the dystrophin-deficient heart showed a drastic increase of
antibodies during aging of the mdx mouse. This finding sug-
gests a possible role of autoimmunity inmuscular dystrophy-
related cardiomyopathy or antibody penetration into muscle
cells through leaky membranes. It is not known whether the
increased antibody levels are a pathophysiological effect or a
triggering factor of cardiomyopathy.
Other interesting proteins with elevated levels in the dys-
trophic heart are represented by transferrin, ferritin andGSH
transferase. Since mammalian cells require sufficient iron
levels for metabolic maintenance, transferrin levels are an
important indicator of potential changes in iron absorption
and usage [44]. Transferrin is an essential circulating protein
that delivers iron to tissue proteins [45], thus changed levels
of this transporter protein is indicative of disturbed cardiac
iron homeostasis in muscular dystrophy. Another key player
in iron metabolism is ferritin, a ubiquitous intracellular iron-
binding protein [46]. Ferritins sequester and release iron in a
highly regulated fashion, thereby serving the dual physiolog-
ical functions of iron detoxification and iron reserve [47]. Its
elevated level in the mdx heart suggests that ferritin buffers
against a potential iron overload in the dystrophic phenotype.
GSH transferase is a crucial catalyst in theGSH-dependent
biotransformation of xenobiotics [48] and elevated levels
therefore suggest increased stress levels in the mdx heart. In
skeletal and cardiac muscle, GSH transferases also form ion
channels in intracellular membrane systems and have been
shown tomodulate the ryanodine receptor Ca2+-release chan-
nel [49]. Thus, a higher concentration of GSH transferases
could also be a compensatory mechanism to counteract ab-
normal Ca2+ handling in muscular dystrophy. The fact that
increased protein oxidation by reactive-free radical species
induces muscle cell damage in both Duchenne patients [50]
and themdxmouse [51] and the establishment of alteredGSH
metabolism in oxidative damage [52], makes the proteomic
identification of GSH transferase and catalase an interesting
finding. As reviewed by Tidball and Wehling-Henricks [53],
the collapse of the dystrophin–glycoprotein complex appears
to disrupt the normal production of free radicals and thereby
contributes to the pathophysiology of muscular dystrophies.
This might be due to constitutive differences in free radical
production and concomitant disruption of crucial signalling
processes in contractile fibres and/or a shift in free radical
production, which promotes cellular injury and contractile
dysfunction [53]. With respect to the mdx heart, changes in
ROS and oxidative damage were shown to be involved in
the molecular pathogenesis of cardiac dysfunction [54]. It is
therefore possible that GSH transferase might be involved
in an antioxidant response in the dystrophic heart. Increased
catalase levels for the enhanced removal of hydrogen per-
oxide would also agree with this concept of an antioxidant
mechanism in mdx tissue. A recent study by Selsby [55] sug-
gests that an elevated expression of catalase improves muscle
function in mdx mice, hence a high concentration of catalase
could play a crucial role in decreasing cellular injury in the
dystrophin-deficient myocardium.
Both proteomics and immunoblotting demonstrated dif-
ferential expression levels of laminin, nidogen and annexin
in normal versus dystrophic hearts at the two different ages
studied. This indicates abnormalities in the extracellular ma-
trix, basement membrane and cytoskeletal network of the
dystrophin-deficient heart. Laminin is an essential compo-
nent of the basementmembrane and critical for the structural
integrity of the extracellularmatrix. Changes in laminin affect
interactions between associated cells due to altered patterns
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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Figure 1. Gel electrophoretic analysis and immunoblotting survey of cardiac proteins in young versus aged normal and dystrophic mdx
mice. A representative Silver-stained gel is shown in panel A. Corresponding immunoblots with expanded views illustrate immuno-
decorated bands (B–F). The immunoblot analysis of heart-associated proteins was performed with antibodies to transferrin (B), laminin
(C), ATP synthase (D), nidogen (E) and annexin (F). Molecular mass standards (in kDa) are indicated on the left of panel A. Lanes 1
to 4 represent normal 7-wk-old hearts, normal 20-month-old hearts, 7-wk-old mdx hearts and 20-month-old mdx hearts, respectively.
Underneath individual immunolots are shown graphical presentation of the statistical evaluation of immuno-decorations. The comparative
blotting between 7-wk-old mdx hearts and 20-month old mdx hearts was statistically evaluated using an unpaired Student’s t-test (n = 5;
*p < 0.05; **p < 0.01). The concentration of laminin, nidogen and annexin was found to be significantly different between young and old
mdx hearts.
of adhesion, differentiation and migration [56]. An abnormal
laminin function is clearly involved in altered cell–matrix in-
teractions in muscle disease [57]. Laminin forms complexes
with nidogen, a sulphated glycoprotein [58], in specialised
basement membranes [59]. In general, changes in basement
membrane composition facilitate pathological mechanisms
[60]. In addition, annexins play a central role in maintenance
of cytoskeleton and extracellular matrix integrity [61], as well
as Ca2+ handling in the heart [62]. A previous analysis of an-
nexin in dystrophin-deficient skeletal muscles has indicated
that certain annexin isoforms are gradually released from the
sarcolemmalmembrane into the cytosol and into the extracel-
lular space during the progression of dystrophinopathy [63].
In analogy, dystrophy-associated cardiomyopathy appears to
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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Figure 2. Immunoblot analysis of cardiac proteins in aging and
dystrophic mdx mice. Shown are representative immunoblots
with expanded views of immuno-decorated bands (A–D). Im-
munoblotting was carried out with antibodies to pyruvate de-
hydrogenase (A; PDH), aconitase (B), malate dehydrogenase (C;
MDH) and mitochondrial porin isoform VDAC1 (D). Lanes 1 to 4
represent normal 7-wk-old hearts, normal 20-month-old hearts,
7-wk-old mdx hearts and 20-month-old mdx hearts, respectively.
Underneath individual immunolots are shown graphical pre-
sentation of the statistical evaluation of immuno-decorations.
The comparative blotting between 7-wk-old mdx hearts and
20-month-old mdx hearts was statistically evaluated using an un-
paired Student’s t-test (n = 5; *p < 0.05). The concentration of
pyruvate dehydrogenase, aconitase, malate dehydrogenase and
VDAC1was found to be significantly different between young and
old mdx hearts.
be also characterised by a drastic reduction in annexin –which
in turnmight be responsible for the decreased levels of the cy-
toskeletal protein vimentin. While the natural aging process
is associated with an increased density of cardiac laminin,
nidogen and annexin, muscular dystrophy triggers a severe
reduction in these structural heart proteins. Thus, the defi-
ciency in cardiac dystrophin seems to have a major desta-
bilising effect on the fibre periphery and its linkage to the
extracellular matrix and cytoskeleton. These molecular and
cellular changes are probably key events that cause cardiomy-
opathic complications and might explain the severe clinical
phenotype of the heart in dystrophinopathy [6]. In addition,
the age-dependent decrease in the nuclear protein lamin in
the dystrophic mdx heart might destabilise nuclear integrity,
transcriptional control and chromatin organisation [64], as
well as trigger premature aging in the dystrophin-deficient
heart [65].
The label-free LC-MS analysis of the aged mdx heart has
identified disturbed levels of a variety of mitochondrial pro-
teins and a general trend of increased glycolytic enzymes.
This suggests considerable metabolic changes and potential
adaptations in dystrophin-deficient heart tissue. Increased
mitochondrial enzymes included isocitrate dehydrogenase,
creatine kinase, isovaleryl-CoA dehydrogenase, aldehyde de-
hydrogenase and long-chain specific acyl-CoA dehydroge-
nase. In contrast, reduced levels were established for the
mitochondrial proteins ATP synthase, NADH dehydroge-
nase, succinate dehydrogenase, cytochrome b-c1 complex,
cytochrome c oxidase, succinyl-CoA ligase and long-chain
fatty acid CoA ligase. The reduction in key components of
themitochondrial electron transport chain suggests impaired
oxidative phosphorylation. Lower levels of the mitochondrial
complex V enzyme ATP synthase, which plays a central role
in the biochemical generation of ATP, would agree with a
reduced ATP production in mdx hearts [66]. A reduction in
critical elements of cardiac mitochondria would contribute in
a major way to a bioenergetic crisis in dystrophin-deficient
tissue, as previously suggested by a gel electrophoresis-based
proteomic study of the mdx heart [16]. It has long been
established that impaired mitochondrial metabolism plays
an important pathogenic feature in dystrophinopathy. Mito-
chondria from mdx skeletal muscle were shown to exhibit
significant uncoupling of oxidative phosphorylation and a re-
duction in maximal ATP synthesis capacity, which results
in decreased intramuscular ATP levels [67]. A recent study
by Percival and co-workers [68] has shown that the lack of
the membrane cytoskeletal protein dystrophin disrupts the
subsarcolemmal localisation of mitochondria, promotes mi-
tochondrial inefficiency and restricts maximal mitochondrial
ATP-generating capacity. The proteomic analysis of the aged
mdx heart presented here agrees with this idea of a bioen-
ergetic dysfunction of mitochondria and suggests that the
inability of mdx heart mitochondria to meet ATP demand
increases during aging. The observed increased expression
of glycolysis-associated enzymes could be interpreted as a
compensatory mechanism to stabilise ATP levels. Thus, the
increase in phosphoglycerate mutase, aldolase, glucose-6-
phosphate isomerase, triosephosphate isomerase and lactate
dehydrogenase might be a natural mechanism to counteract
the pathophysiological loss of mitochondrial ATP production
and at least partially balance the metabolic need for ATP in
the dystrophic heart. This would suggest a general tendency
to an oxidative-to-glycolytic shift in cardiac mdx metabolism.
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Based on the previous finding that dystrophin deficiency
causes a drastic decrease in the dystrophin-connected /-
dystroglycan complex in the mdx heart [30], we could show
here that additional secondary changes appear to trigger the
loss in key extracellular matrix linker proteins. Alterations
down-stream from the direct binding partners of the dys-
trophin complex have previously been established, including
lower levels of the sarcoplasmic reticulum Ca2+-buffering
proteins sarcalumenin and calsequestrin in the membrane
fraction from dystrophic hearts [32]. In addition, here we
could show by label-free LC-MS/MS analysis that secondary
effects influence the concentration of ferritin, tranferrin,
catalase, GSH transferase, laminin, nidogen and annexin,
as well as a large number of enzymes involved in both
anaerobic and oxidative metabolism. Aging of the mdx heart
appears to have a profound influence on many structural
proteins and metabolic enzymes. Ion transportation, the cel-
lular stress response, ion handling and the maintenance of
the contractile apparatus seem to be affected in dystrophin-
deficient heartmuscle. Dystrophinopathy-associated changes
in a broad range of cardiac proteins supports the idea of se-
vere pathobiochemical complications in aged mdx mice and
establishes this genetic model as a suitable system to evaluate
new drug treatments to counteract cardiomyopathy.
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